Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility

References

• Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13:785–796.
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Bulitta JB, Landersdorfer CB. Combination therapy for carbapenem-resistant gram-negative bacteria. Expert Rev Anti Infect Ther. 2013;11:1333–1353. Epub 2013/11/07.
   PubMed Web of Science ®Google Scholar
• Almaghrabi R, Clancy CJ, Doi Y, et al. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Antimicrob Agents Chemother. 2014;58:4443–4451. Epub 2014/05/29.
   PubMed Web of Science ®Google Scholar
• Bremmer DN, Clancy CJ, Press EG, et al. Shields RK. KPC-producing Klebsiella pneumoniae strains that harbor AAC(6ʹ)-Ib exhibit intermediate resistance to amikacin. Antimicrob Agents Chemother. 2014;58:7597–7600. Epub 2014/10/08.
   PubMed Web of Science ®Google Scholar
• Monaco M, Giani T, Raffone M, et al. Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014. Euro Surveill. 2014 Oct 23;19(42): pii: 20939.
   PubMedGoogle Scholar
• Kontopidou F, Giamarellou H, Katerelos P, et al. Group for the Study of KPCpKpiiicu. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect. 2014;20:O117–23.
   PubMed Web of Science ®Google Scholar
• Bartolleti F, Seco BM, Capuzzo Dos Santos C, et al. Polymyxin B resistance in carbapenem-resistant Klebsiella pneumoniae, Sao Paulo, Brazil. Emerg Infect Dis. 2016;22:1849–1851. Epub 2016/09/21.
   PubMed Web of Science ®Google Scholar
• Vidal L, Gafter-Gvili A, Borok S, et al. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2007;60:247–257. Epub 2007/06/15.
   PubMed Web of Science ®Google Scholar
• Milatovic D, Braveny I. Development of resistance during antibiotic therapy. Eur J Clin Microbiol. 1987;6:234–244. Epub 1987/06/01.
   PubMedGoogle Scholar
• Zhanel GG, Lawson CD, Zelenitsky S, et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther. 2012;10:459–473. Epub 2012/04/20.
   PubMed Web of Science ®Google Scholar
• Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother. 2005;56:128–132. Epub 2005/05/27.
   PubMed Web of Science ®Google Scholar
• Endimiani A, Hujer AM, Perez F, et al. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother. 2009;63:427–437. Epub 2009/01/22.
   PubMed Web of Science ®Google Scholar
• Endimiani A, Hujer KM, Hujer AM, et al. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 2009;53:4504–4507. Epub 2009/09/23.
   PubMed Web of Science ®Google Scholar
• Haidar G, Alkroud A, Cheng S, et al. Association between the presence of aminoglycoside-modifying enzymes and in vitro activity of gentamicin, tobramycin, amikacin, and plazomicin against Klebsiella pneumoniae carbapenemase- and extended-spectrum-beta-lactamase-producing Enterobacter species. Antimicrob Agents Chemother. 2016;60:5208–5214. Epub 2016/06/15.
   PubMed Web of Science ®Google Scholar
• Lopez-Camacho E, Gomez-Gil R, Tobes R, et al. Genomic analysis of the emergence and evolution of multidrug resistance during a Klebsiella pneumoniae outbreak including carbapenem and colistin resistance. J Antimicrob Chemother. 2014;69:632–636. Epub 2013/10/25.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Avial I, Pena I, Picazo JJ, et al. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains. Int J Antimicrob Agents. 2015;46:616–621. Epub 2015/09/24.
   PubMed Web of Science ®Google Scholar
• Drusano GL, Ambrose PG, Bhavnani SM, et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis. 2007;45:753–760.
   PubMed Web of Science ®Google Scholar
• CLSI. Performance standards for antimicrobial susceptibility testing. PA, USA: Document M100-S26 Wayne; 2016.
   Google Scholar
• Bulitta JB, Ly NS, Landersdorfer CB, et al. Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling. Antimicrob Agents Chemother. 2015;59:2315–2327.
   PubMed Web of Science ®Google Scholar
• Yadav R, Landersdorfer CB, Nation RL, et al. Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2015;59:2286–2298.
   PubMed Web of Science ®Google Scholar
• Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin North Am. 2003;17:503–28, v. Epub 2004/01/09.
   PubMed Web of Science ®Google Scholar
• Lacy MK, Nicolau DP, Nightingale CH, et al. The pharmacodynamics of aminoglycosides. Clin Infect Dis. 1998;27:23–27. Epub 1998/07/24.
   PubMed Web of Science ®Google Scholar
• Rees VE, Bulitta JB, Oliver A, et al. Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa. J Antimicrob Chemother. 2016;71:3157–3167.
   PubMed Web of Science ®Google Scholar
• Beauchamp D, Labrecque G. Aminoglycoside nephrotoxicity: do time and frequency of administration matter? Curr Opin Crit Care. 2001;7:401–408. Epub 2002/01/24.
   PubMedGoogle Scholar
• Yadav R, Bulitta JB, Nation RL, et al. Optimization of synergistic combination regimens against carbapenem- and aminoglycoside-resistant clinical Pseudomonas aeruginosa isolates via mechanism-based pharmacokinetic/pharmacodynamic modeling. Antimicrob Agents Chemother. 2016 Dec 27;61(1): pii: e01011-16.
   Web of Science ®Google Scholar
• Brasseur A, Hites M, Roisin S, et al. A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study. J Antimicrob Chemother. 2016 May;71(5):1386–1394.
   PubMed Web of Science ®Google Scholar
• Roger C, Nucci B, Louart B, et al. Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis. J Antimicrob Chemother. 2016;71:208–212.
   PubMed Web of Science ®Google Scholar
• White BP, Lomaestro B, Pai MP. Optimizing the initial amikacin dosage in adults. Antimicrob Agents Chemother. 2015;59:7094–7096.
   PubMed Web of Science ®Google Scholar
• Roger C, Nucci B, Molinari N, et al. Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations. Int J Antimicrob Agents. 2015;46:21–27.
   PubMed Web of Science ®Google Scholar
• Blackburn LM, Tverdek FP, Hernandez M, et al. First-dose pharmacokinetics of aminoglycosides in critically ill haematological malignancy patients. Int J Antimicrob Agents. 2015;45:46–53.
   PubMed Web of Science ®Google Scholar
• De Montmollin E, Bouadma L, Gault N, et al. Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen. Intensive Care Med. 2014;40:998–1005.
   PubMed Web of Science ®Google Scholar
• Galvez R, Luengo C, Cornejo R, et al. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents. 2011;38:146–151.
   PubMed Web of Science ®Google Scholar
• Taccone FS, Laterre PF, Spapen H, et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care. 2010;14:R53.
   PubMed Web of Science ®Google Scholar
• Burdet C, Pajot O, Couffignal C, et al. Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia. Eur J Clin Pharmacol. 2015;71:75–83.
   PubMed Web of Science ®Google Scholar
• Rea RS, Capitano B, Bies R, et al. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit. 2008;30:674–681.
   PubMed Web of Science ®Google Scholar
• European Committee on Antimicrobial Susceptibility Testing. EUCAST clinical MIC breakpoints. www.eucast.org, accessed 07 February 2017. Available from: www.eucast.org.
   Google Scholar
• Gonzalez-Padilla M, Torre-Cisneros J, Rivera-Espinar F, et al. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2015;70:905–913.
   PubMed Web of Science ®Google Scholar
• Shields RK, Clancy CJ, Press EG, et al. Aminoglycosides for treatment of bacteremia due to carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother. 2016;60:3187–3192. Epub 2016/03/02.
   PubMed Web of Science ®Google Scholar
• Brown SA, Riviere JE. Comparative pharmacokinetics of aminoglycoside antibiotics. J Vet Pharmacol Ther. 1991;14:1–35. Epub 1991/03/01.
   PubMed Web of Science ®Google Scholar
• Alexander BT, Marschall J, Tibbetts RJ, et al. Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort. Clin Ther. 2012;34:1314–1323. Epub 2012/06/14.
   PubMed Web of Science ®Google Scholar
• Rodrigues Dos Santos BG, Amaral ES, Fernandes PF, et al. Urinary tract infections and surgical site infections due to carbapenem-resistant Enterobacteriaceae in renal transplant. Transplant Proc. 2016;48:2050–2055. Epub 2016/08/30.
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Kubin CJ, Blumenthal JS, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother. 2011;55:5893–5899. Epub 2011/10/05.
   PubMed Web of Science ®Google Scholar
• Van Duin D, Cober E, Richter SS, et al. Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2015;70:1203–1211. Epub 2014/12/11.
   PubMed Web of Science ®Google Scholar
• Paquette F, Bernier-Jean A, Brunette V, et al. Acute kidney injury and renal recovery with the use of aminoglycosides: a large retrospective study. Nephron. 2015;131:153–160.
   PubMed Web of Science ®Google Scholar
• Avent ML, Rogers BA, Cheng AC, et al. Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity. Intern Med J. 2011;41:441–449. Epub 2011/02/12.
   PubMed Web of Science ®Google Scholar
• Maglio D, Nightingale CH, Nicolau DP. Extended interval aminoglycoside dosing: from concept to clinic. Int J Antimicrob Agents. 2002;19:341–348. Epub 2002/04/30.
   PubMed Web of Science ®Google Scholar
• Tod M, Padoin C, Petitjean O. Clinical pharmacokinetics and pharmacodynamics of isepamicin. Clin Pharmacokinet. 2000;38:205–223. Epub 2000/04/05.
   PubMed Web of Science ®Google Scholar
• Ong LZ, Tambyah PA, Lum LH, et al. Aminoglycoside-associated acute kidney injury in elderly patients with and without shock. J Antimicrob Chemother. 2016 Nov;71(11):3250-3257.
   Web of Science ®Google Scholar
• Guthrie OW. Aminoglycoside induced ototoxicity. Toxicology. 2008;249:91–96.
   PubMed Web of Science ®Google Scholar
• Drusano GL, Bonomo RA, Bahniuk N, et al. Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012;56:231–242. Epub 2011/10/19.
   PubMed Web of Science ®Google Scholar
• Hirsch EB, Guo B, Chang KT, et al. Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. Pneumoniae J Infect Dis. 2013;207:786–793.
   PubMed Web of Science ®Google Scholar
• Le J, McKee B, Srisupha-Olarn W, et al. In vitro activity of carbapenems alone and in combination with amikacin against KPC-producing Klebsiella pneumoniae. J Clin Med Res. 2011;3:106–110.
   PubMedGoogle Scholar
• Tang HJ, Lai CC, Chen CC, et al. Colistin-sparing regimens against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates: combination of tigecycline or doxycycline and gentamicin or amikacin. J Microbiol Immunol Infect. 2016 Mar 31; pii: S1684-1182(16)30024-X.
   Google Scholar
• Paul M, Carmeli Y, Durante-Mangoni E, et al. Combination therapy for carbapenem-resistant gram-negative bacteria. J Antimicrob Chemother. 2014;69:2305–2309. Epub 2014/05/30.
   PubMed Web of Science ®Google Scholar
• Zusman O, Altunin S, Koppel F, et al. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother. 2017 Jan;72(1):29-39.
   Web of Science ®Google Scholar
• Falagas ME, Mavroudis AD. Vardakas KZ. The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect? Expert Rev Anti Infect Ther. 2016;14:747–763. Epub 2016/07/13.
   PubMed Web of Science ®Google Scholar
• USCAST. Aminoglycoside in vitro susceptibility test interpretive criteria evaluations. http://www.uscast.org/news/aminoglycoside-in-vitro-susceptibility-test-interpretation-criteria-evaluations-now-available-for-public-comment2016.
   Google Scholar